Clinical trial · people
Tesamorelin: model accurately predicted GH and IGF-1 over 14 days
Checked against the paper Clinical trialPublished by PepVault
The takeaway
In early short trials, GH and IGF-1 levels on daily tesamorelin followed a predictable pattern, and none of the traits checked, including HIV status, showed a significant link to it.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 41
- Published
- 2015
- Journal
- J Pharmacokinet Pharmacodyn
What they tested
The team wanted to map how growth hormone (GH) and insulin-like growth factor (IGF-1) levels change over time with daily tesamorelin, and whether traits like age, weight or HIV status were linked to that pattern.
How the study was done
A modeling analysis that pooled Phase I trials covering 41 people with HIV or healthy volunteers, each given a daily under-the-skin dose of 1 or 2 mg of tesamorelin for 14 days in a row. The team built a model of GH and then IGF-1 levels, starting from an earlier model of tesamorelin blood levels.

Model. Individual results vary.
What they found
The model accurately predicted GH and IGF-1 levels over time after repeated tesamorelin doses. It passed checks that compare predictions with real data and that resample the data many times. Within the range of values studied, none of age, body weight, body mass index, sex, race or health status (HIV or healthy) was significantly linked to the GH or IGF-1 model results.
What it doesn’t show
The model was built from 41 people in Phase I trials over 14 days and tracked only GH and IGF-1 levels. The results on age, weight, sex, race and HIV status hold only within the range of values evaluated.
The paper
González-Sales et al. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. J Pharmacokinet Pharmacodyn. 2015.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.